欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此洽谈。
;如有合作推广需求,请近期推荐: | 热 SCI论文AI润色+人工QC服务 | 热 同行专家帮助选刊 | 热 Springer Nature特刊征稿 |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | ANTI-CANCER DRUGS ANTI-CANCER DRUG (此期刊被最新的JCR期刊SCIE收录) LetPub评分 5.7
55人评分
我要评分
声誉 6.5 影响力 4.4 速度 8.7 | |||||||||||||||||||||||||||||||
期刊ISSN | 0959-4973 | ![]() 蝌蝌APP,让您与同行交流更轻松
![]() | ||||||||||||||||||||||||||||||
E-ISSN | 1473-5741 | |||||||||||||||||||||||||||||||
2024-2025最新影响因子 (数据来源于搜索引擎) | 2.2 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||
实时影响因子 | 截止2025年5月19日:2.136 | |||||||||||||||||||||||||||||||
2024-2025自引率 | 4.50%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||
五年影响因子 | 1.9 | |||||||||||||||||||||||||||||||
JCI期刊引文指标 | 0.61 | |||||||||||||||||||||||||||||||
h-index | 88 | |||||||||||||||||||||||||||||||
CiteScore ( 2025年最新版) |
| |||||||||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||||||||
期刊官方网站 | http://journals.lww.com/anti-cancerdrugs/pages/default.aspx | |||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||
期刊投稿网址 | https://www.editorialmanager.com/ACD | |||||||||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足ANTI-CANCER DRUGS的语言要求,还能让ANTI-CANCER DRUGS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被ANTI-CANCER DRUGS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(2篇) 。
提交文稿 | |||||||||||||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||||||||||||
通讯方式 | LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621 | |||||||||||||||||||||||||||||||
出版商 | Lippincott Williams and Wilkins Ltd. | |||||||||||||||||||||||||||||||
涉及的研究方向 | 医学-药学 | |||||||||||||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||||||||
出版周期 | Monthly | |||||||||||||||||||||||||||||||
出版年份 | 1990 | |||||||||||||||||||||||||||||||
年文章数 | 121点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||
Gold OA文章占比 | 21.23% | |||||||||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 96.69% | |||||||||||||||||||||||||||||||
WOS期刊SCI分区 ( 2024-2025年最新版) | WOS分区等级:3区
| |||||||||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0959-4973%5BISSN%5D | |||||||||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 偏慢,4-8周 | |||||||||||||||||||||||||||||||
平均录用比例 | 网友分享经验: 容易 | |||||||||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在ANTI-CANCER DRUGS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(2篇) 。 提交文稿 | |||||||||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report Author: Yang, Guangjian; Hu, Jiaqi; Liu, Runze; Li, Pei; Yang, Linke; Tang, Xiaoyong; Wang, Luokun Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 432-437. DOI: 10.1097/CAD.0000000000001695 PubMed DOI |
2. | Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature Author: Yang, Can; Zhang, Cui; Huang, Yisidan; Zhu, Xiong; Jiang, Jia; Zeng, Yuting; Zhang, Hanqun; Li, Libo; Liu, Yuncong; Li, Yong Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. -. DOI: 10.1097/CAD.0000000000001702 PubMed DOI |
3. | Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study Author: Xu, Chang; Ren, Jing; Liu, Changqing; Gai, Yi; Cheng, Xiangyu; Wang, Yusheng; Wang, Guangyu Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 383-393. DOI: 10.1097/CAD.0000000000001697 PubMed DOI |
4. | Combined protein and transcriptomics identifies DCTPP1 as a putative biomarkers for predicting immunotherapy responsiveness in gastric cancer patients Author: Wei, Jun; Qin, Yuexuan; Zhang, Luwen; Gong, Xiaobing Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 415-426. DOI: 10.1097/CAD.0000000000001704 PubMed DOI |
5. | Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment Author: Tan, Tingfei; Yuan, Siyu; Chu, Weiwei; Jiang, Jiemei; Chen, Meiling; Xia, Quan; Wang, Junping Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 408-414. DOI: 10.1097/CAD.0000000000001701 PubMed DOI |
6. | Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years Author: Su, Wenzhong; Li, Jianqiang Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 401-407. DOI: 10.1097/CAD.0000000000001699 PubMed DOI |
7. | A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer Author: Li, Siyuan; Zhang, Yanqin; Yang, Rong; Yang, Qingfan; Han, Shuangyan; Li, Dan; Zhang, Zhenhua; Wen, Qinglian Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 394-400. DOI: 10.1097/CAD.0000000000001698 PubMed DOI |
8. | BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells Author: Jia, Zhu-xia; Xiao, Bi-tao; Li, Jin; Cai, Xiao-hui; Qin, Wei; Zhou, Min; Lu, Xu-zhang Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 374-382. DOI: 10.1097/CAD.0000000000001696 PubMed DOI |
9. | Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report Author: Guo, Yanrong; Zhai, Jinfang; Yang, Yanli; Wei, Qin; Li, Shengshu; Huo, Rujie; Tong, Guoping; Xu, Enwei; Chen, Yan; Han, Songyan; Chen, Deyi Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 427-431. DOI: 10.1097/CAD.0000000000001693 PubMed DOI |
10. | BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway Author: Deng, Yingcheng; Li, Yilin; Cao, Hong Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 359-373. DOI: 10.1097/CAD.0000000000001694 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室